Oct 09, 2024 7:03am EDT Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
Sep 24, 2024 7:03am EDT Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
Sep 16, 2024 7:03am EDT Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
Sep 05, 2024 7:03am EDT Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Sep 03, 2024 7:03am EDT Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Aug 26, 2024 7:03am EDT Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024
Aug 14, 2024 7:10am EDT Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
Jul 17, 2024 7:03am EDT Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
Jul 11, 2024 7:03am EDT Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Jul 10, 2024 7:03am EDT Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)
